555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [trại gà đá tây ninh]
Important Safety Information Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is contraindicated in patients with a history of severe systemic reactions to the product or to A1-PI protein, including …
A controlled, double-blind study in 44 subjects who received weekly 60 mg/kg body weight dose of either Zemaira (30 subjects) or Prolastin® (a commercially available Alpha1-Proteinase Inhibitor …
Sep 30, 2024 · Zemaira package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
ZEMAIRA® Prescribing InformationImportant Safety Information Alpha 1 -Proteinase Inhibitor (Human), ZEMAIRA ® is indicated to raise the plasma level of alpha 1 -proteinase inhibitor (A 1 …
Sep 23, 2024 · ZEMAIRA is supplied in a single-dose vial containing the amount of functionally active A1-PI printed on the vial label and carton. The product presentations include a package …
ZEMAIRA is contraindicated in patients with a history of severe systemic reactions to the product or to A 1 -PI protein, including anaphylaxis. Due to the risk of severe hypersensitivity, ZEMAIRA is …
Table of Contents Zemaira Product Label The following document was submitted to the FDA by the labeler of this product Fisher Clinical Services Inc.. The document includes published materials …
Jan 31, 2024 · CBER Zemaira Product Approval InformationSTN: 125078 Proper Name: Alpha-1-Proteinase Inhibitor (Human) Tradename: ZEMAIRA Manufacturer: CSL Behring LLC Indication: …
The effect of augmentation therapy with ZEMAIRA or any A1-PI product on pulmonary exacerbations and on the progression of emphysema in A1-PI deficiency has not been …
The recommended weekly dose of ZEMAIRA is 60 mg/kg body weight. Dose ranging studies using efficacy endpoints have not been performed with ZEMAIRA or any A1-PI product (2).
Bài viết được đề xuất: